As Clovis Oncology (Call) (CLVS) Market Value Declined, Holder Brookside Capital Management Has Decreased Position; Oakworth Capital Boosted Holding in Jp Morgan Chase & Company (JPM) as Market Value Rose

April 21, 2018 - By Hazel Jackson

Clovis Oncology, Inc. (NASDAQ:CLVS) Logo

Bain Capital decreased its stake in Clovis Oncology Inc (Call) (CLVS) by 98.58% based on its latest 2017Q4 regulatory filing with the SEC. Brookside Capital Management Llc sold 208,851 shares as the company’s stock declined 18.56% with the market. The hedge fund run by Bain Capital held 3,000 shares of the health care company at the end of 2017Q4, valued at $375,000, down from 211,851 at the end of the previous reported quarter. Brookside Capital Management Llc who had been investing in Clovis Oncology Inc (Call) for a number of months, seems to be less bullish one the $2.54 billion market cap company. The stock decreased 2.24% or $1.15 during the last trading session, reaching $50.17. About 1.18 million shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 21.43% since April 21, 2017 and is downtrending. It has underperformed by 32.98% the S&P500.

Oakworth Capital Inc increased its stake in Jp Morgan Chase & Company (JPM) by 7.43% based on its latest 2017Q4 regulatory filing with the SEC. Oakworth Capital Inc bought 7,668 shares as the company’s stock rose 0.67% while stock markets declined. The institutional investor held 110,818 shares of the major banks company at the end of 2017Q4, valued at $11.58M, up from 103,150 at the end of the previous reported quarter. Oakworth Capital Inc who had been investing in Jp Morgan Chase & Company for a number of months, seems to be bullish on the $380.16B market cap company. The stock decreased 0.22% or $0.25 during the last trading session, reaching $111.47. About 15.58 million shares traded. JPMorgan Chase & Co. (NYSE:JPM) has risen 23.99% since April 21, 2017 and is uptrending. It has outperformed by 12.44% the S&P500.

Since October 25, 2017, it had 2 buys, and 9 selling transactions for $20.34 million activity. CROWN JAMES S also bought $825,327 worth of JPMorgan Chase & Co. (NYSE:JPM) on Tuesday, January 16. The insider HOBSON MELLODY L bought $2.00M. On Saturday, January 13 Erdoes Mary E. sold $7.31M worth of JPMorgan Chase & Co. (NYSE:JPM) or 65,101 shares. Petno Douglas B also sold $5.43 million worth of JPMorgan Chase & Co. (NYSE:JPM) shares. On Saturday, January 13 the insider Lake Marianne sold $1.03 million. Friedman Stacey had sold 17,729 shares worth $1.99 million on Saturday, January 13.

Among 34 analysts covering JPMorgan Chase & Co (NYSE:JPM), 18 have Buy rating, 2 Sell and 14 Hold. Therefore 53% are positive. JPMorgan Chase & Co had 119 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of JPMorgan Chase & Co. (NYSE:JPM) earned “Outperform” rating by Wells Fargo on Thursday, August 10. On Tuesday, August 16 the stock rating was downgraded by Bernstein to “Market Perform”. The stock of JPMorgan Chase & Co. (NYSE:JPM) earned “Buy” rating by Bank of America on Friday, January 12. The rating was maintained by Oppenheimer with “Hold” on Thursday, July 20. On Wednesday, February 21 the stock rating was maintained by Morgan Stanley with “Overweight”. BMO Capital Markets maintained the shares of JPM in report on Thursday, June 1 with “Hold” rating. As per Friday, July 7, the company rating was maintained by Jefferies. The firm has “Overweight” rating by Morgan Stanley given on Friday, February 2. The company was maintained on Tuesday, June 6 by Jefferies. The rating was upgraded by Credit Agricole on Tuesday, August 25 to “Outperform”.

Oakworth Capital Inc, which manages about $424.98M US Long portfolio, decreased its stake in Walt Disney Productions (NYSE:DIS) by 4,585 shares to 67,590 shares, valued at $7.09M in 2017Q4, according to the filing. It also reduced its holding in Honeywell International Inc (NYSE:HON) by 2,714 shares in the quarter, leaving it with 354 shares, and cut its stake in Int’l Business Machines Corp (NYSE:IBM).

Investors sentiment decreased to 0.88 in Q4 2017. Its down 0.03, from 0.91 in 2017Q3. It worsened, as 55 investors sold JPM shares while 802 reduced holdings. 142 funds opened positions while 611 raised stakes. 2.46 billion shares or 1.60% less from 2.50 billion shares in 2017Q3 were reported. 13,913 were reported by Blue Edge Limited Liability Co. 46,714 are owned by Kj Harrison Prtn Incorporated. 79,250 were accumulated by Compton Cap Mgmt Inc Ri. Pineno Levin Ford Asset Mgmt has 2,226 shares for 0.1% of their portfolio. Birinyi owns 27,612 shares or 1.32% of their US portfolio. Iron Lc has 6,984 shares for 0.52% of their portfolio. 512,813 are owned by Boston Advisors Llc. Wellcome Tru (The) As Trustee Of The Wellcome Tru holds 4.70M shares or 7.6% of its portfolio. Trustco Fincl Bank Corporation N Y owns 3.98% invested in JPMorgan Chase & Co. (NYSE:JPM) for 36,098 shares. Doheny Asset Mgmt Ca holds 6,133 shares. Addenda holds 0.59% of its portfolio in JPMorgan Chase & Co. (NYSE:JPM) for 79,664 shares. Ct Mason has 3.72% invested in JPMorgan Chase & Co. (NYSE:JPM) for 98,793 shares. Davis R M owns 47,722 shares for 0.2% of their portfolio. Elkhorn Prns Limited Partnership has invested 0.22% in JPMorgan Chase & Co. (NYSE:JPM). Mogy Joel R Counsel reported 0.11% in JPMorgan Chase & Co. (NYSE:JPM).

Since December 15, 2017, it had 0 insider buys, and 7 sales for $1.64 million activity. $192,480 worth of Clovis Oncology, Inc. (NASDAQ:CLVS) was sold by IVERS-READ GILLIAN C on Friday, December 15.

Analysts await Clovis Oncology, Inc. (NASDAQ:CLVS) to report earnings on May, 2. They expect $-1.34 earnings per share, down 0.75% or $0.01 from last year’s $-1.33 per share. After $-1.27 actual earnings per share reported by Clovis Oncology, Inc. for the previous quarter, Wall Street now forecasts 5.51% negative EPS growth.

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 64 analyst reports since September 10, 2015 according to SRatingsIntel. WallachBeth Capital maintained Clovis Oncology, Inc. (NASDAQ:CLVS) on Monday, May 9 with “Hold” rating. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Friday, January 27 by Bank of America. As per Monday, November 16, the company rating was maintained by Piper Jaffray. On Monday, July 31 the stock rating was maintained by Oppenheimer with “Hold”. The firm earned “Outperform” rating on Thursday, February 22 by RBC Capital Markets. As per Wednesday, September 21, the company rating was upgraded by Credit Suisse. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) has “Buy” rating given on Monday, September 11 by Stifel Nicolaus. The company was downgraded on Monday, November 16 by Mizuho. The firm earned “Neutral” rating on Wednesday, August 24 by Mizuho. The company was maintained on Tuesday, February 27 by Barclays Capital.

Investors sentiment decreased to 1.05 in Q4 2017. Its down 0.39, from 1.44 in 2017Q3. It dropped, as 35 investors sold CLVS shares while 69 reduced holdings. 31 funds opened positions while 78 raised stakes. 49.09 million shares or 3.43% more from 47.46 million shares in 2017Q3 were reported. Susquehanna Ltd Liability Partnership invested in 0.01% or 366,173 shares. Wolverine Asset Ltd accumulated 2,363 shares. Prudential holds 50,740 shares. 4,025 are held by Bb&T Limited. Rhumbline Advisers invested 0.01% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS). Cap Impact Advisors owns 21,881 shares or 0.64% of their US portfolio. Tekla Cap Mngmt Ltd Llc holds 75,400 shares or 0.2% of its portfolio. Venbio Select Advisor Ltd Co has 4.86% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 1.10M shares. Amundi Pioneer Asset owns 0.01% invested in Clovis Oncology, Inc. (NASDAQ:CLVS) for 52,800 shares. Landscape Capital Limited Liability reported 23,657 shares. Clough Capital Partners LP reported 153,735 shares stake. Bnp Paribas Arbitrage holds 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 9,093 shares. Point72 Asia (Hong Kong) Limited has invested 0.02% in Clovis Oncology, Inc. (NASDAQ:CLVS). 3,277 were reported by Lpl Fin Limited Liability Corp. stated it has 29,600 shares.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: